The direct-to-consumer longevity testing industry has a problem, and it's not scientific—it's existential. Give someone a biological age of 42 when their driver's license says 38, and what then? A vague suggestion to "reduce stress" and "eat more vegetables"?
NiaHealth thinks the entire model is backwards.
The Toronto-based startup, which secured $5.75 million in seed funding this past July, launched NiaAge beta on November 17—a biological age assessment that refuses to let customers off easy. No cheek swab in the mail. No algorithm-generated PDF. Instead: comprehensive blood testing for up to 150 biomarkers, followed by mandatory video consultations with actual physicians or nurse practitioners trained in longevity medicine.
It's an expensive, deliberately old-fashioned approach in a market racing toward automation. Whether it's defensible—or scalable—depends on a wager that consumers will pay more for context than convenience.
"We're not interested in giving people a biological age score that leaves them asking, 'Now what?'" the company said in its beta announcement. Which sounds obvious enough. Except most of the industry has decided that "now what" is the customer's problem.
Beyond the Bloodwork
NiaAge analyzes markers across cardiovascular, metabolic, inflammatory, and hormonal systems—roughly ten times what you'd see in a routine physical, according to the company. The model draws on validation work against one of Canada's largest longitudinal health datasets, though NiaHealth hasn't published peer-reviewed studies or released technical specifics. (They say publication is coming. No timeline yet.)
Unlike epigenetic clocks—those DNA methylation tests that companies like TruDiagnostic sell for $499 or more—NiaAge focuses on functional performance rather than mortality risk. Think less "your cells are aging like a 50-year-old's" and more "here's why your inflammation markers suggest your body is working harder than it should."
Users can drill into which parameters are dragging their score down: lipid panels, glucose control, inflammatory markers. The dashboard surfaces these alongside normal ranges and historical trends, assuming you test more than once.
Early data—limited, self-reported, but suggestive—shows 60 percent of members who retested annually improved their biological age by an average of 1.4 years. Women saw bigger shifts: 1.8 years on average. Men, about 1.1 years.
Whether those improvements reflect actual health gains or statistical noise is another question entirely. But the company is betting that giving people something concrete to work on beats handing them a number and wishing them luck.
The Clinician Bottleneck
Every NiaHealth member gets a written summary and video consultation with a clinician—often Tanya ter Keurs, the nurse practitioner who co-founded the company and now runs clinical operations as Chief Clinical Officer, or one of the MDs and NPs on staff.
This past fall, the company brought on Dr. Emma Olive Billington, a Calgary endocrinologist with more than 50 peer-reviewed publications, as Head of Clinical Research. Her background in bone health and nutrition hints at where NiaHealth may be building depth beyond standard biomarker interpretation—though exactly how remains to be seen.
"We're building something that bridges the gap between 'your bloodwork looks normal' and actually optimizing for long-term health," ter Keurs told Longevity.Technology in an earlier interview. The clinicians develop personalized plans: specific dietary tweaks, supplement protocols, exercise prescriptions. Not generic. Not algorithmic. Just slower and more expensive than software alone.
Which is precisely the problem, if you're trying to scale.
A Market Still Figuring Itself Out
The biological age space has gotten crowded fast, though the approaches vary wildly.
TruDiagnostic and Elysium Health have built businesses around epigenetic testing in CLIA-certified labs, charging north of $500 for DNA methylation analysis. Tally Health offers cheek-swab tests starting at $229, though customer reviews often pan the generic recommendations. InsideTracker uses 13 to 17 blood biomarkers weighted by machine learning—some coaching included, but no mandatory physician consult. GlycanAge takes a different route entirely, analyzing immune system glycan patterns, with Canadian clinics charging around $485 CAD per test.
The academic world keeps churning out alternatives. In June, researchers at the National University of Singapore published LinAge2, a clinical clock designed for practical aging assessment. That same month, University of Washington scientists introduced "Health Octo," an eight-metric tool derived from routine exams that predicts disability and mortality.
NiaHealth's multi-biomarker, clinician-reviewed model sits somewhere between pure algorithmic tests and traditional medicine. Call it a hybrid—or call it hedging. Either way, it's unclear whether consumers will pay a premium for the human touch, or whether better outcomes will justify the approach. The beta will tell.
Fast Growth, Open Questions
The company has moved with surprising speed since emerging from stealth. It raised $2.5 million CAD in a pre-seed round in late 2023, led by Version One Ventures, then closed an oversubscribed $5.75 million seed in July led by Golden Ventures. The investor roster includes executives from Fullscript, Shopify, and CIBC, plus several U.S. longevity-focused funds.
By late July, NiaHealth had administered more than 140,000 biomarker tests and was projecting 300,000 by year-end. The platform operates across nine Canadian provinces, with pricing from $299 CAD annually for 40-plus biomarkers (Essential tier) to packages bundling 150-plus markers, DEXA scans, VO2 max testing, and continuous glucose monitors.
The company claims its customer base includes first-responder organizations, CEOs, and Olympic athletes—though it offered no specifics on enterprise partnerships beyond research collaborations with the University of Alberta and health company Ada for employer benefits channels. Which is to say: there's momentum, but the details remain fuzzy.
What Happens After Beta
NiaAge launches with the usual startup caveats. No independent peer review yet. Limited technical disclosure. Outcome data that's early-stage at best.
Platform expansion is already underway—wearables integration from Oura, Apple, Garmin, and Fitbit; continuous glucose monitoring programs; expanded biomarker panels including heavy metal screening and advanced thyroid tests. Whether those additions sharpen the biological age assessment or just pad the feature list isn't clear. Maybe both.
What NiaHealth is really testing is whether biological age testing can escape the trap that's ensnared so much of direct-to-consumer health tech: algorithms that promise clarity but deliver confusion, numbers stripped of context, recommendations so generic they might as well be fortune cookies.
The company's answer—put a clinician in every transaction—is more expensive and harder to scale than software ever will be. It's also, perhaps, more honest about what health insights actually require. Not just data. Not just algorithms. But someone who can look at your results and tell you what they mean for you.
In a market still figuring out what actually helps people live better and longer, that might matter more than anyone expected.
